Welcome to our dedicated page for Mobia Medical SEC filings (Ticker: MOBI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mobia Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mobia Medical's regulatory disclosures and financial reporting.
Mobia Medical, Inc. (MOBI) director Casey M. Tansey reported an open-market purchase of 16,441 shares of common stock on August 18, 2026 at a weighted average price of $12.0749 per share. Following this transaction, Tansey directly holds 318,332 shares of Mobia Medical common stock. The purchase price reflects multiple trades executed between $11.90 and $12.70 per share.
Mobia Medical, Inc. director Casey M Tansey reported open-market purchases of 68,559 shares of common stock over three days in August 2026. Transactions included 35,572 shares on August 13 at a weighted average price of $11.5073, 15,821 shares on August 14 at weighted average and fixed prices, and 17,166 shares on August 17 at a weighted average price of $11.8509. Footnotes state that several reported prices are weighted averages based on multiple trades within disclosed price ranges. The Rule 10b5-1 checkbox was not marked as an affirmatively adopted trading plan.
Mobia Medical, Inc. received a beneficial ownership report from Green Park & Golf Ventures II, LLC and a group of affiliated investment entities and individuals. The Reporting Persons disclose 3,684,409 shares of Mobia Medical common stock, which they state represents 11.1% of the class.
The stake is held across numerous Delaware and Texas limited liability companies, including Green Park & Golf Ventures II, Green Park & Golf Ventures – Houston, and multiple GPG- and MTI-branded vehicles. Clay M. Heighten, MD, Carl D. Soderstrom and Gilbert G. Garcia II are managers of the managing entities and share voting and dispositive power, and may be deemed to beneficially own the securities held by these entities.
The ownership percentages are based on 33,291,096 shares outstanding as of August 6, 2026, as reported by Mobia Medical in a prior Form 10-Q. All reported powers over the shares are described as shared rather than sole.
Mobia Medical, Inc. has a significant ownership position reported by U.S. Venture Partners–affiliated entities and an individual director under a Schedule 13G. U.S. Venture Partners XII, L.P. reports beneficial ownership of 1,906,809 shares of common stock, representing 5.7% of the outstanding shares, with shared voting and dispositive power over all of these shares.
Presidio Management Group XII, L.L.C. reports beneficial ownership of 3,626,826 shares, or 10.9% of Mobia Medical’s common stock, all with shared voting and dispositive power. Casey M. Tansey, a U.S. citizen and a member of the issuer’s board, reports beneficial ownership of 3,860,158 shares, or 11.6%, including 233,332 shares over which he has sole voting and dispositive power and the remainder with shared power through venture funds.
All percentages are based on 33,249,006 shares of common stock outstanding as of June 1, 2026. The reporting persons state that they are not acting as a group and each disclaims beneficial ownership beyond any pecuniary interest.
Mobia Medical, Inc. reports strong top-line growth but continued losses for the six months ended June 30, 2026. Revenue was $25.6 million, up from $12.3 million, with a high gross margin of about 83%. Operating expenses increased sharply, led by selling, general and administrative costs, resulting in a net loss of $38.8 million versus $21.1 million a year earlier.
In May 2026 the company completed an IPO, selling 10,000,000 shares at $15.00 per share for net proceeds of about $134.0 million. All 65.6 million preferred shares and $40.0 million of convertible notes converted into common stock, moving from a stockholders’ deficit to $172.6 million of equity. Cash and cash equivalents rose to $177.1 million, and management now concludes existing liquidity is sufficient for at least one year, so prior substantial-doubt going-concern language no longer applies.
Mobia Medical, Inc. reported second quarter 2026 results with revenue of $13.5 million, an increase of 102% from $6.7 million a year earlier, driven by higher adoption of the Vivistim System and more IPG units sold. Gross profit was $11.2 million, and gross margin was 83.2% compared with 82.3% in the prior-year quarter.
Operating expenses rose to $29.2 million, up 83% from $16.0 million, reflecting expanded commercial personnel, commissions, development, and administrative costs. Net loss was $21.0 million, or $1.10 per share, versus a net loss of $10.5 million, or $12.44 per share, mainly due to higher expenses and a change in fair value of convertible notes.
As of June 30, 2026, cash and cash equivalents totaled $177.1 million, including approximately $134.0 million in net proceeds from an initial public offering completed in May 2026. For full year 2026, the company expects revenue of $54.0 million to $56.0 million, representing growth of 69% to 75% over 2025.
Mobia Medical, Inc. director Myriam Curet received two stock option awards on 2026-07-30: one for 19,740 options and another for 15,960 options, each exercisable for common stock at an exercise price of $11.1800 per share. The first option vests in three substantially equal annual installments on the first three anniversaries of the grant date; the second fully vests at the 2027 Annual Meeting under the Non-Employee Director Compensation Policy. Both options expire on 2036-07-30.
Mobia Medical, Inc. director Myriam Curet has filed an initial insider ownership report for the company. The disclosure identifies her role as a director, reports no equity transactions or derivative positions, and notes an attached Exhibit 24 Power of Attorney authorizing the filing on her behalf.
Mobia Medical, Inc. expanded its Board of Directors from seven to eight members effective July 30, 2026 and appointed Myriam J. Curet, M.D. as a new Class II director. Her term runs until the company’s 2028 annual meeting of stockholders, or until a successor is elected and qualified.
The Board determined that Dr. Curet qualifies as an independent director under SEC and Nasdaq rules. She is not yet assigned to any Board committee and will receive compensation under Mobia’s non-employee director compensation program, along with the company’s standard indemnification agreement. The company states there are no related-party transactions with Dr. Curet requiring disclosure.
Mobia Medical, Inc. director Reza Zadno received two stock option awards covering 16,260 and 19,150 shares of common stock at an exercise price of $11.57 per share, expiring on July 14, 2036. Vesting schedules include three substantially equal annual installments and full vesting at the 2027 Annual Meeting.